Global Companion Diagnostics Partnering Terms and Agreements 2010-2020
|出版商||Current Partnering, a division of Wildwood Ventures Limited||商品編碼||230289|
|出版日期||內容資訊||英文 300+ Pages
|搭配診斷相關合作契約:交易趨勢，企業，財務及預測 Global Companion Diagnostics Partnering Terms and Agreements 2010-2020|
|出版日期: 2020年05月01日||內容資訊: 英文 300+ Pages||
Current Partnering Current Agreements CurrentPartnering的發行標題
The Global Companion Diagnostics Partnering 2010-2020 report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies
The Global Companion Diagnostics Partnering 2010-2020 report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.
Trends in companion diagnostics partnering deals
Companion diagnostics partnering agreement structure
Companion diagnostics partnering contract documents
Top companion diagnostics deals by value
Most active companion diagnostics dealmakers
The report provides a detailed understanding and analysis of how and why companies enter Companion Diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.
This report provides details of the latest Companion Diagnostics agreements announced in the life sciences since 2010.
The report takes the reader through a comprehensive review Companion Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Companion Diagnostics partnering deals.
The report presents financial deal term values for Companion Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the Companion Diagnostics partnering field; both the leading deal values and most active Companion Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 450 online deal records of actual Companion Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
The initial chapters of this report provide an orientation of Companion Diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Companion Diagnostics dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading Companion Diagnostics deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in Companion Diagnostics dealmaking with a brief summary followed by a comprehensive listing of Companion Diagnostics deals announded by that company, as well as contract documents, where available.
Chapter 5 provides a comprehensive and detailed review of Companion Diagnostics partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of Companion Diagnostics partnering deals signed and announced since Jan 2010. The chapter is organized by specific Companion Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
A comprehensive series of appendices is provided organized by Companion Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Companion Diagnostics partnering and dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Companion Diagnostics technologies and products.
Global Companion Diagnostics Partnering 2010-2020: Deal trends, players, financials and forecasts provides the reader with the following key benefits:
Companion Diagnostics Partnering Terms and Agreements includes:
In Global Companion Diagnostics Partnering 2010-2020: Deal trends, players, financials and forecasts, the available deals are listed by:
Analyzing actual contract agreements allows assessment of the following:
Global Companion Diagnostics Partnering 2010-2020 provides the reader with the following key benefits: